Report overview
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
This report aims to provide a comprehensive presentation of the global market for Parkinson's Disease (PD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson's Disease (PD) Drugs. This report contains market size and forecasts of Parkinson's Disease (PD) Drugs in global, including the following market information:
Global Parkinson's Disease (PD) Drugs Market Revenue, 2018-2023, 2024-2035, ($ millions)
Global Parkinson's Disease (PD) Drugs Market Sales, 2018-2023, 2024-2035, (K Pcs)
Global top five Parkinson's Disease (PD) Drugs companies in 2022 (%)
The global Parkinson's Disease (PD) Drugs market was valued at US$ 5651 million in 2022 and is projected to reach US$ 7494.1 million by 2035, at a CAGR of 4.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
We surveyed the Parkinson's Disease (PD) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Parkinson's Disease (PD) Drugs Market, by Type, 2018-2023, 2024-2035 ($ Millions) & (K Pcs)
Global Parkinson's Disease (PD) Drugs Market Segment Percentages, by Type, 2022 (%)
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
Global Parkinson's Disease (PD) Drugs Market, by Application, 2018-2023, 2024-2035 ($ Millions) & (K Pcs)
Global Parkinson's Disease (PD) Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Family
Global Parkinson's Disease (PD) Drugs Market, By Region and Country, 2018-2023, 2024-2035 ($ Millions) & (K Pcs)
Global Parkinson's Disease (PD) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Parkinson's Disease (PD) Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Parkinson's Disease (PD) Drugs revenues share in global market, 2022 (%)
Key companies Parkinson's Disease (PD) Drugs sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Parkinson's Disease (PD) Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer
Outline of Major Chapters:
Chapter 1: Introduces the definition of Parkinson's Disease (PD) Drugs, market overview.
Chapter 2: Global Parkinson's Disease (PD) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Parkinson's Disease (PD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Parkinson's Disease (PD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Parkinson's Disease (PD) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
